301258 Suzhou Fushilai Pharmaceutical
- 29.11
- -0.79-2.64%
Suzhou Fushilai Pharmaceutical News
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
Synthetic biology concept stocks opened and fell, and Xinghu Technology hit a fall. Lukang Pharmaceutical, Shuangta Foods, and Weilan Biotech fell by more than 5%, while Fujilai, Hualu Biotech, Yiduoli, and Ruifeng High Materials followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology sector weakened, with Xintiandi falling more than 8%, Fujilai falling nearly 6%, and many stocks such as Lukang Pharmaceutical, Canaan Technology, and Kyodo Pharmaceutical followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
The synthetic biology concept bottomed out and rebounded. In 7 days and 4, Xintiandi surged more than 10%, while Rundu Co., Ltd., Fujilai, Tuoxin Pharmaceuticals, and Rhine Biotech followed suit.
Fujilai (301258.SZ): No plans for cellular immunotherapy
Gelonghui, May 10 | Fujilai (301258.SZ) said on the investor interactive platform that the company has no plans for cellular immunotherapy yet.
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
A-share synthetic biology concept shares open 5 consecutive blue biotechnology boards
Glonghui, May 7 | Azure Biotech 5 in a row. Fujilai is close to rising or stopping. Boen Group, Lukang Pharmaceutical, Chuan Ning Biotech, and Borui Pharmaceuticals are opening high.
The synthetic biology concept continues to be active, with Fujilai exceeding 19%
The synthetic biology concept continues to be active. Fujilai surpassed 19%; Blue Biotech, Guangji Pharmaceutical, and Qianjiang Biochemical bids rose and stopped, and Boen Group and Lukang Pharmaceutical all went up and down.
Express News | Double-sided Fujilai: R-lipoic acid produced by bioenzymatic catalysis accounts for a relatively small revenue share, and there are no clear plans to expand production
Fujilai (301258.SZ): R-lipoic acid produced by enzymatic method has been mass-produced and sold abroad
Gelonghui, May 6 | Fujilai (301258.SZ) said on the investor interactive platform that R-lipoic acid produced by the company's enzymatic method has been mass-produced and is currently still in the marketing stage. Whether it can completely replace the original process depends on various factors such as market demand and customer acceptance.
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Synthetic biology concept stocks continued to explode. Lu Kang Pharmaceutical rose and stopped in the afternoon. Many stocks such as Twining Biotech, Fujilai, Shengda Biotech, Blue Biotech, and Yiduoli closed, and Fuxiang Pharmaceutical and Jiabiyou rose
Synthetic biology concept stocks continued to explode. Lu Kang Pharmaceutical rose and stopped in the afternoon. Many stocks such as Twining Biotech, Fujilai, Shengda Biotech, Blue Biotech, and Yiduoli closed, and Fuxiang Pharmaceutical and Jiabiyou rose more than 10%.
Fujilai (301258.SZ): Net profit of 5.786,800 yuan in the first quarter decreased by 88.79% year on year
Gelonghui, April 22 | Fujilai (301258.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 96.2913 million yuan, down 38.47% year on year; net profit attributable to shareholders of listed companies was 5.7868 million yuan, down 88.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.1951 million yuan, down 92.87% year on year; basic earnings per share were 0.0631 yuan.
Fujilai (301258.SZ): Currently not involved in the production of anti-nuclear radiation products
Gelonghui, April 12 | Fujilai (301258.SZ) said on the investor interactive platform that the company is currently not involved in the production of anti-nuclear radiation products. In the pharmaceutical field, lipoic acid is used to treat various diseases such as diabetic peripheral neuropathy and neurological complications; in the field of health products, it has the effect of removing free radicals from the body and preventing lipid peroxidation, and can delay aging, beauty, and activate cells, and is used in oral nutritional products.
Fujilai (301258.SZ): Supervisor Qian Yi plans to reduce holdings by no more than 562,000 shares
Gelonghui, April 2 | Fujilai (301258.SZ) announced that Supervisor Qian Yi plans to reduce her holdings of no more than 56,200 shares through centralized bidding, accounting for 0.0613% of the company's total share capital after excluding the repurchase of shares, within 3 months of 15 trading days from the date of the announcement of the capital reduction plan.
Fujilai (301258.SZ): Total number of shareholders as of March 29, 2024 was 1,1811
Gelonghui, April 2 | Fujilai (301258.SZ) said on the investor interactive platform that the total number of shareholders as of March 29, 2024 was 11,811.
Fujilai (301258.SZ): Total number of shareholders as of March 8, 2024 was 11,370
Gelonghui March 11 | Fujilai (301258.SZ) said on the investor interactive platform that the total number of shareholders as of March 8, 2024 was 11,370.
Fujilai (301258.SZ): Initial repurchase of 10,000 shares involving 252,400 yuan
Gelonghui (301258.SZ) announced on March 1, 2024, that on February 29, 2024, the number of shares of the company was repurchased for the first time through a special stock repurchase securities account with a centralized bidding transaction of 10,000 shares, accounting for 0.0109% of the company's current total share capital. The highest transaction price was 25.28 yuan/share, the minimum transaction price was 25.20 yuan/share, and the total capital used was 252,400 yuan (excluding transaction fees).
Express News | Fujilai: Plans to buy back shares for 20 million yuan to 40 million yuan
Fujilai (301258.SZ) has been re-certified as a high-tech enterprise
Gelonghui, Feb. 20 | Fujilai (301258.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: [GR202332000244], date of issue: November 6, 2023, validity period: three years.
Fujilai (301258.SZ) performance report: 2023 net profit of 113 million yuan fell 36.38% year on year
Gelonghui, Feb. 19 | Fujilai (301258.SZ) announced its 2023 annual results report. According to preliminary accounting, in 2023, the company achieved total operating revenue of 489 million yuan, down 13.89% from the same period of the previous year; operating profit of 135 million yuan, down 34.42% from the same period of the previous year; total profit of 129 million yuan, down 36.07% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss 8915,500 yuan, compared to
Analysis
Price Target
No Data
